Market Overview

Piper Jaffray Overweight On Vertex Pharmaceuticals (VRTX)


Piper Jaffray has an Overweight rating and a $48 price target on shares of Vertex Pharmaceuticals (NASDAQ: VRTX).

In a note sent to clients, Piper Jaffray writes, "We expect Vertex to Outperform in 2011 as the company launches blockbuster Telaprevir. We anticipate accelerated approval by the likely May 23rd PDUFA date. We forecast rapid Telaprevir adoption as U.S. hepatologists treat motivated HCV patients. Telaprevir will drive profitability as Vertex becomes cash flow positive in 4Q:11. We anticipate Vertex will either buy or partner for additional HCV drugs to build out its combination portfolio. Despite the Inspire miss, VX-770 could provide a second drug approval in 2012. Lastly, we anticipate Vertex will strengthen its cash position with another convertible note deal."

Shares of VRTX gained $1.35 yesterday to close at $36.84, a gain of 3.8%.

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Latest Ratings

WHDB of A SecuritiesMaintains35.0
TALDeutsche BankInitiates Coverage On68.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at